arrow_back Trending Legislation
Share share

Biosimilar Education: Better Information for Patients and Healthcare Providers.

This new law aims to increase knowledge about biosimilar medications among patients, caregivers, and healthcare professionals. This will enable citizens to better understand their treatment options and make informed health decisions, potentially impacting drug accessibility and costs.
Key points
An internet website will be created to provide educational materials on biosimilar products, explaining key terms and usage guidelines.
Healthcare providers will gain access to continuing education programs to better prescribe and understand biosimilar medications.
Information on reporting adverse events for biosimilar products will be more readily available to everyone.
article Official text account_balance Process page notifications_active Track this Bill
98%
VOTING RESULTS
2021-04-14
For 412
Against 8
Abstain 0
Full voting results open_in_new
gavel
Status:
Became Law
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Advancing Education on Biosimilars Act of 2021
Print number: S 164
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
Process start date: 2021-02-02
Voting date: 2021-04-14
Meeting no: 1
Voting no: 101
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Biosimilar Education: Better Information for Patients and Healthcare Providers.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 164.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-02.

What are the main provisions?

Key points include:

  • An internet website will be created to provide educational materials on biosimilar products, explaining key terms and usage guidelines.
  • Healthcare providers will gain access to continuing education programs to better prescribe and understand biosimilar medications.
  • Information on reporting adverse events for biosimilar products will be more readily available to everyone.

What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Sen. Hassan, Margaret Wood [D-NH].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-8.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of S 164

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health